The Estée Lauder Companies Inc. · EL · FY2027 Q1 · Calendar Q4 2026
Estée Lauder Raises FY2027 Outlook as Fragrance Drives Q1 Growth
The latest call analysis indicates momentum has strengthened: reported organic sales growth and fragrance performance accompanied another increase to the FY2027 outlook. That supports the operating-recovery case, while the durability of growth and execution against cost, inventory and luxury-demand risks remain unproven.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about EL FY2027 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported 6% Q1 organic sales growth, with fragrance up 20% and performance across regions, and raised its full-year outlook. The call analysis also noted higher consumer-facing investment, lower capex, and the completed Forest Essentials acquisition.
Guidance delta
Raised FY2027 organic sales outlook to 4%–5.5% and operating-margin outlook to 12.9%–13.7%, from the prior-quarter ranges of 3%–5% and 12.7%–13.5%.
Key takeaways
- Q1 organic sales growth was 6%, with fragrance up 20% and strength described across regions.
- The FY2027 organic sales and operating-margin outlooks were raised.
- Consumer-facing investment increased while capex was reduced, according to the call analysis.
- Management cited innovation, online/social commerce and One ELC efficiency efforts as growth and execution priorities.
Management priorities
- Extend fragrance launches and expand the prestige fragrance portfolio.
- Grow online and social commerce, including TikTok Shop and brand.com.
- Integrate Forest Essentials and expand its footprint.
- Advance One ELC initiatives across media, e-commerce and back-office efficiency.
Follow EL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 2, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Overweight | Overweight | Maintain | Oct 23, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 22, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 19, 2026 |
| Jefferies | Hold | Hold | Maintain | Oct 19, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 15, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Oct 5, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Oct 5, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 20, 2026 |
| Telsey Advisory Group | Market Perform | Market Perform | Maintain | Aug 20, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 20, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 20, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Aug 20, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 20, 2026 |
| B. Riley Securities | Neutral | Neutral | Maintain | Aug 20, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | Mar 30, 2026 |
| Raymond James | Strong Buy | Market Perform | Upgrade | Jan 5, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Dec 16, 2025 |
| Rothschild & Co | Sell | Neutral | Downgrade | Nov 25, 2025 |
| Argus Research | Buy | Hold | Upgrade | Nov 11, 2025 |
| HSBC | Buy | Hold | Upgrade | Jun 27, 2025 |
| Stifel | Hold | Hold | Maintain | Apr 10, 2025 |
| DA Davidson | Buy | Buy | Maintain | Feb 25, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Nov 1, 2024 |
| Oppenheimer | Perform | Perform | Maintain | Apr 15, 2024 |
| Berenberg | Hold | Buy | Downgrade | Nov 3, 2023 |
| Redburn Atlantic | Neutral | Sell | Upgrade | Sep 15, 2023 |
| Bernstein | Market Perform | Outperform | Downgrade | Aug 24, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 6, 2023 |
| Redburn Partners | Sell | Sell | Maintain | Dec 15, 2022 |
| Piper Jaffray | Neutral | Overweight | Downgrade | Oct 28, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 20, 2019 |
| Bank of America | Buy | Buy | Maintain | Aug 20, 2019 |
| Macquarie | Outperform | Outperform | Maintain | May 2, 2019 |
| D.A. Davidson | Neutral | Buy | Downgrade | May 2, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 2, 2019 |
| Atlantic Equities | Overweight | Overweight | Maintain | Sep 20, 2018 |
| B. Riley FBR | Neutral | Buy | Downgrade | May 5, 2018 |
| Argus | Hold | Buy | Downgrade | May 5, 2018 |
| KeyBanc | Overweight | Overweight | Maintain | Nov 2, 2017 |
| Societe Generale | Hold | Buy | Downgrade | May 5, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Mar 2, 2017 |
| CSLA | Underperform | Buy | Downgrade | Nov 3, 2016 |
| CLSA | Underperform | Buy | Downgrade | Nov 3, 2016 |
| B. Riley | Neutral | Neutral | Maintain | Nov 3, 2015 |
| FBR Capital | Outperform | Outperform | Maintain | Aug 21, 2015 |
Named analyst price targets
Upside is calculated against the persisted current price $104.86. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Scotiabank | Analyst unavailable | $125 | $107.99 | +19.2% | Oct 23, 2026 |
| Piper Sandler | Analyst unavailable | $125 | $107.72 | +19.2% | Oct 23, 2026 |
| Canaccord Genuity | Susan Anderson | $109 | $103.66 | +3.9% | Oct 22, 2026 |
| Goldman Sachs | Bonnie Herzog | $124 | $104.65 | +18.2% | Oct 19, 2026 |
| Jefferies | Analyst unavailable | $120 | $104.54 | +14.4% | Oct 19, 2026 |
| Bernstein | Cristian Rios | $114 | $106.99 | +8.7% | Oct 16, 2026 |
| Barclays | Lauren Lieberman | $108 | $91.97 | +3.0% | Oct 5, 2026 |
| Berenberg Bank | Fulvio Cazzol | $92 | $104.1 | -12.3% | Aug 25, 2026 |
| Telsey Advisory | Analyst unavailable | $108 | $97.72 | +3.0% | Aug 20, 2026 |
| Deutsche Bank | Analyst unavailable | $117 | $97.48 | +11.6% | Aug 20, 2026 |
| Jefferies | Sydney Wagner | $100 | $97.1 | -4.6% | Aug 20, 2026 |
| RBC Capital | Analyst unavailable | $120 | $96.86 | +14.4% | Aug 20, 2026 |
| Piper Sandler | Analyst unavailable | $115 | $98.01 | +9.7% | Aug 20, 2026 |
| Bernstein | Cristian Rios | $106 | $98.01 | +1.1% | Aug 20, 2026 |
| Canaccord Genuity | Susan Anderson | $90 | $98.01 | -14.2% | Aug 20, 2026 |
| Morgan Stanley | Dara Mohsenian | $102 | $98.01 | -2.7% | Aug 20, 2026 |
| Barclays | Analyst unavailable | $97 | $98.01 | -7.5% | Aug 20, 2026 |
| Wells Fargo | Analyst unavailable | $104 | $98.01 | -0.8% | Aug 20, 2026 |
| Goldman Sachs | Analyst unavailable | $112 | $98.01 | +6.8% | Aug 19, 2026 |
| Seaport Global | Analyst unavailable | $95 | $87.03 | -9.4% | Aug 14, 2026 |
| Jefferies | Analyst unavailable | $88 | $83.2 | -16.1% | Jul 28, 2026 |
| Cowen & Co. | Analyst unavailable | $90 | $82.12 | -14.2% | Jul 21, 2026 |
| Barclays | Analyst unavailable | $80 | $83.64 | -23.7% | Jul 21, 2026 |
| UBS | Peter Grom | $86 | $82.75 | -18.0% | Jul 16, 2026 |
| Goldman Sachs | Bonnie Herzog | $100 | $84.81 | -4.6% | Jun 22, 2026 |
| Bernstein | Cristian Rios | $82 | $88.02 | -21.8% | Jun 11, 2026 |
| Piper Sandler | Analyst unavailable | $95 | $80.83 | -9.4% | May 15, 2026 |
| Barclays | Analyst unavailable | $75 | $81.33 | -28.5% | May 5, 2026 |
| UBS | Peter Grom | $85 | $81.7 | -18.9% | May 4, 2026 |
| Telsey Advisory | Dana Telsey | $90 | $82.25 | -14.2% | May 4, 2026 |
| Morgan Stanley | Dara Mohsenian | $90 | $81.96 | -14.2% | May 4, 2026 |
| Wells Fargo | Analyst unavailable | $85 | $79.3 | -18.9% | May 4, 2026 |
| Barclays | Lauren Lieberman | $72 | $74.86 | -31.3% | Apr 14, 2026 |
| RBC Capital | Nik Modi | $111 | $73.29 | +5.9% | Apr 9, 2026 |
| Wells Fargo | Analyst unavailable | $75 | $71.44 | -28.5% | Apr 8, 2026 |
| HSBC | Erwan Rambourg | $106 | $99.01 | +1.1% | Feb 10, 2026 |
| Wells Fargo | Analyst unavailable | $105 | $96.66 | +0.1% | Feb 6, 2026 |
| UBS | Analyst unavailable | $107 | $96.66 | +2.0% | Feb 6, 2026 |
| Barclays | Lauren Lieberman | $94 | $96.66 | -10.4% | Feb 6, 2026 |
| Deutsche Bank | Steve Powers | $128 | $115.4 | +22.1% | Jan 29, 2026 |
| Argus Research | Analyst unavailable | $140 | $117.69 | +33.5% | Jan 26, 2026 |
| Barclays | Analyst unavailable | $100 | $114.22 | -4.6% | Jan 16, 2026 |
| UBS | Analyst unavailable | $119 | $115.37 | +13.5% | Jan 14, 2026 |
| Jefferies | Analyst unavailable | $110 | $115.37 | +4.9% | Jan 14, 2026 |
| Wells Fargo | Analyst unavailable | $111 | $107.58 | +5.9% | Jan 5, 2026 |
| Raymond James | Strong Buy | $130 | $106.76 | +24.0% | Jan 5, 2026 |
| Evercore ISI | Robert Ottenstein | $125 | $102.46 | +19.2% | Dec 16, 2025 |
| Redburn Partners | Chris Pitcher | $70 | $93.39 | -33.2% | Nov 25, 2025 |
| Barclays | Analyst unavailable | $91 | $96.69 | -13.2% | Nov 3, 2025 |
| RBC Capital | Nik Modi | $113 | $97.33 | +7.8% | Oct 31, 2025 |
| UBS | Peter Grom | $105 | $96.63 | +0.1% | Oct 31, 2025 |
| Canaccord Genuity | Analyst unavailable | $100 | $102.16 | -4.6% | Oct 27, 2025 |
| Goldman Sachs | Analyst unavailable | $115 | $87.65 | +9.7% | Oct 13, 2025 |
| Canaccord Genuity | Susan Anderson | $85 | $91.2 | -18.9% | Aug 18, 2025 |
| Berenberg Bank | Analyst unavailable | $60 | $66.08 | -42.8% | Mar 25, 2025 |
| Telsey Advisory | Dana Telsey | $76 | $66.58 | -27.5% | Nov 1, 2024 |
| Stifel Nicolaus | Mark Astrachan | $125 | $87.15 | +19.2% | Oct 31, 2024 |
| Deutsche Bank | Steve Powers | $98 | $89.26 | -6.5% | Oct 22, 2024 |
| HSBC | Erwan Rambourg | $100 | $90.93 | -4.6% | Oct 16, 2024 |
| Evercore ISI | Robert Ottenstein | $130 | $85.13 | +24.0% | Sep 10, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $130 | $92.53 | +24.0% | Sep 3, 2024 |
| Piper Sandler | Korinne Wolfmeyer | $114 | $93.99 | +8.7% | Aug 22, 2024 |
| Telsey Advisory | Dana Telsey | $105 | $92.85 | +0.1% | Aug 20, 2024 |
| UBS | Peter Grom | $104 | $92.85 | -0.8% | Aug 20, 2024 |
| Deutsche Bank | Steve Powers | $105 | $92.85 | +0.1% | Aug 20, 2024 |
| J.P. Morgan | Andrea Teixeira | $129 | $94.97 | +23.0% | Aug 19, 2024 |
| Bank of America Securities | Bryan Spillane | $100 | $95.14 | -4.6% | Aug 16, 2024 |
| RBC Capital | Nik Modi | $131 | $99.96 | +24.9% | Jul 24, 2024 |
| Barclays | Lauren Lieberman | $117 | $96.9 | +11.6% | Jul 19, 2024 |
| Barclays | Lauren Lieberman | $136 | $113.93 | +29.7% | Jun 14, 2024 |
| Morgan Stanley | Dara Mohsenian | $140 | $132.94 | +33.5% | May 3, 2024 |
| Raymond James | Olivia Tong | $155 | $132.51 | +47.8% | May 2, 2024 |
| Telsey Advisory | Dana Telsey | $142 | $127.37 | +35.4% | May 2, 2024 |
| Wells Fargo | Chris Carey | $175 | $138.21 | +66.9% | Apr 17, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $191 | $138.8 | +82.1% | Apr 15, 2024 |
| Piper Sandler | Korinne Wolfmeyer | $158 | $145.43 | +50.7% | Apr 9, 2024 |
| RBC Capital | Nik Modi | $195 | $162.93 | +86.0% | Aug 16, 2023 |
| Telsey Advisory | Dana Telsey | $250 | $205.81 | +138.4% | May 8, 2023 |
| Canaccord Genuity | Susan Anderson | $228 | $222.91 | +117.4% | Nov 16, 2022 |
| Goldman Sachs | Jason English | $303 | $239.5 | +188.9% | Sep 20, 2022 |
| Morgan Stanley | Dara Mohsenian | $320 | $265.1 | +205.2% | Aug 22, 2022 |
| UBS | Peter Grom | $289 | $281.62 | +175.6% | Aug 19, 2022 |
| Telsey Advisory | Dana Telsey | $377 | $281.75 | +259.5% | Aug 18, 2022 |
| RBC Capital | Nik Modi | $322 | $249.12 | +207.1% | May 4, 2022 |
| Credit Suisse | Analyst unavailable | $320 | $246.14 | +205.2% | May 4, 2022 |
| Deutsche Bank | Analyst unavailable | $289 | $259.28 | +175.6% | Apr 27, 2022 |
| Piper Sandler | Analyst unavailable | $350 | $275.1 | +233.8% | Apr 19, 2022 |
| Barclays | Lauren Lieberman | $342 | $314.43 | +226.1% | Feb 7, 2022 |
| UBS | Peter Grom | $326 | $312.71 | +210.9% | Feb 4, 2022 |
| Bank of America Securities | Bryan Spillane | $330 | $312.71 | +214.7% | Feb 4, 2022 |
| Goldman Sachs | Jason English | $341 | $302.5 | +225.2% | Feb 3, 2022 |
| Jefferies | Stephanie Wissink | $360 | $302.5 | +243.3% | Feb 3, 2022 |
| Wells Fargo | Christopher Carey | $355 | $302.5 | +238.5% | Feb 3, 2022 |
| Piper Sandler | Korinne Wolfmeyer | $380 | $293.61 | +262.4% | Jan 25, 2022 |
| D.A. Davidson | Linda Bolton Weiser | $439 | $339.07 | +318.6% | Nov 3, 2021 |
| Raymond James | Olivia Tong | $390 | $337.32 | +271.9% | Nov 2, 2021 |
| Societe Generale | Victoria Nice | $335 | $324.8 | +219.5% | Jul 14, 2021 |
Track every rating change on EL the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationThe Estée Lauder Companies Inc. is a global entity dedicated to the development, marketing, and sale of a diverse range of premium beauty and personal care items worldwide. Its extensive product catalog encompasses numerous offerings across four primary categories. For skin care, it provides moisturizers, serums, cleansers, toners, body treatments, exfoliants, acne and oil control solutions, facial masks, specialized cleansing devices, and sun protection. In makeup, consumers can find lipsticks, glosses, mascaras, foundations, eyeshadows, nail polishes, powders, compacts, brushes, and various other cosmetic tools. The fragrance segment includes eau de parfum sprays, colognes, scented lotions, powders, creams, candles, and soaps.…
Historical context
All EL earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CHD Church & Dwight Co., Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | +1.2% | Church & Dwight raises sales outlook after strong Q3 organic growth |
| CL Colgate-Palmolive Company | FY2026 Q3 · Calendar Q4 2026 | +4.8% | +2.3% | Colgate-Palmolive: Broad Growth and Margin Expansion in Q3 |
| MDLZ Mondelez International, Inc. | FY2026 Q3 · Calendar Q4 2026 | +10.2% | +3.9% | Mondelez cites volume growth, innovation and productivity as key levers |
Latest beats and misses
Who reports nextBeat on EPS
- SNYFY2026 Q3 · October 30, 2026+30.8% EPS+2.8% move
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- PINSFY2026 Q3 · October 29, 2026-5.4% EPS-2.8% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the EL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-02T18:05:50.676158+00:00
- FN2 earnings calendar · 2026-11-02T01:23:13.261602+00:00
- Polygon adjusted daily market bars · 2026-11-02T18:20:46.720253+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T18:20:46.717610+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.